Welcome to our dedicated page for Quipt Home Medical news (Ticker: QIPT), a resource for investors and traders seeking the latest updates and insights on Quipt Home Medical stock.
Quipt Home Medical Corp. (QIPT) generates a steady flow of news as a U.S.-based home medical equipment provider focused on end-to-end respiratory care and in-home chronic disease management. Company press releases regularly discuss its role in providing in-home monitoring and disease management services for patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions in the United States healthcare market.
News coverage for QIPT commonly includes financial results and operational updates. For example, Quipt issues quarterly and annual earnings releases that highlight revenue trends, recurring revenue from equipment rentals and respiratory resupplies, Adjusted EBITDA, and operational metrics such as the number of unique patients served and set-ups or deliveries completed. These releases often include management commentary on business performance, revenue stabilization, and the contribution of acquisitions and partnerships.
Another major category of Quipt news involves strategic transactions. The company has announced acquisitions of durable medical equipment providers and a joint venture interest in Hart Medical Equipment, as well as a preferred provider agreement with Ballad Health. These items describe how Quipt works with health systems and hospitals to integrate home medical equipment and respiratory care into hospital discharge processes and post-acute care coordination.
More recently, Quipt’s news has featured corporate and M&A developments, including activist shareholder commentary and, most notably, the December 2025 announcement of a definitive Arrangement Agreement under which a special purpose acquisition vehicle funded by affiliates of Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for cash. This transaction, if completed, is expected to result in Quipt becoming a privately held company and its shares being delisted from The Nasdaq Capital Market and the Toronto Stock Exchange.
Investors and observers using this QIPT news page on Stock Titan can review these earnings announcements, acquisition and joint venture updates, health system partnership news, and transaction-related disclosures in one place, helping them understand how Quipt’s home medical equipment and respiratory care strategy is reflected in its public communications.
Summary not available.
Quipt Home Medical Corp. reported strong financial results for Q1 fiscal 2023, achieving $40.8 million in revenue, a 38% year-over-year increase. Adjusted EBITDA reached $9 million with a 22% margin, up from $6 million (20.3% margin) a year ago. The net income was $325,000 compared to a loss of $2.1 million in Q1 2022. Organic growth increased 2% sequentially, while the company anticipates returning to historical growth levels of 8-10%. The acquisition of Great Elm Healthcare is expected to enhance revenue and EBITDA significantly, projecting annualized figures of $220 million and $49 million, respectively.
Quipt Home Medical Corp. (NASDAQ: QIPT) announced it will host its Fiscal Q1 2023 earnings conference call on February 14, 2023, at 10:00 a.m. (EST). The call aims to provide insights into the company's financial performance and growth strategies in the home medical equipment sector.
The company focuses on end-to-end respiratory care and in-home monitoring, catering to patients with chronic diseases such as heart and pulmonary conditions. Quipt seeks to enhance shareholder value by expanding its service offerings and improving patient care.
Quipt Home Medical Corp. has announced the acquisition of Great Elm Healthcare, effective December 31, 2022. This strategic move enhances Quipt's standing as a leading provider in the U.S. respiratory care market, with combined annualized revenues expected to reach $220 million and anticipated adjusted EBITDA of $49 million. The total purchase price is $80 million, comprising cash, assumed debt, and stock. The acquisition is projected to generate $2 million in cost savings and synergies, alongside expanding Quipt's geographic reach to 270,000 patients across 115 locations in 26 states.
Quipt Home Medical Corp. (NASDAQ:QIPT) reported robust financial results for the fiscal year 2022, achieving revenue of $139.9 million, a 36.6% increase from 2021. The Adjusted EBITDA of $29.2 million represents a 20.9% margin, stable amidst inflationary pressures. Notably, net income turned positive at $4.8 million compared to a loss of $6.2 million in 2021. The customer base grew by 23% to 173,203 unique patients. Quipt's acquisition strategy remains strong, with eight acquisitions completed in 2022. Management anticipates continued growth due to favorable market conditions and a strong balance sheet.
Quipt Home Medical Corp. (NASDAQ: QIPT) announced its Q4 and Full Year Fiscal 2022 earnings conference call on December 22, 2022, at 10:00 a.m. (EST). The call aims to update stakeholders on the Company's performance, focusing on its in-home monitoring and respiratory care services in the U.S. The Company is committed to expanding its chronic disease management offerings. The live audio webcast will be accessible via their investor website, reflecting Quipt's goal to enhance shareholder value through increased annual revenue per patient and a broader range of services.
Quipt Home Medical Corp. announced the closure of $110 million in senior secured credit facilities with CIT Bank, enhancing its financial flexibility. This increase from the initially planned $80 million reflects strong demand from lenders. The funds will primarily be used for future acquisitions and working capital. Quipt aims to leverage this financial resource to pursue organic and inorganic growth in the U.S. healthcare market, focusing on respiratory solutions amidst inflation and supply chain challenges.
Quipt Home Medical Corp. (NASDAQ: QIPT) reported a strong fiscal Q3 2022, with revenue growth of 40% year-over-year, reaching $36.7 million and an adjusted EBITDA increase of 44%, totaling $7.7 million. The company’s recurring revenue constituted 77% of total revenue, reflecting solid operational performance. As of June 30, 2022, the cash flow from operations stood at $19.4 million. Recent acquisitions expanded their reach, adding over 30,000 active patients. The company also secured an $80 million senior credit facility, enhancing financial flexibility.
Quipt Home Medical Corp. announced a binding commitment from CIT Bank for senior secured credit facilities totaling up to $80 million. This financing includes a $5 million term loan, $55 million delayed draw term loan, and $20 million revolving credit facility. The funds will support future acquisitions and working capital. CEO Greg Crawford noted this achievement bolsters their growth strategy and assures a healthy balance sheet. The deal is pending customary conditions, and funding is expected within 30 days.
Quipt Home Medical Corp. (NASDAQ: QIPT) will host a webcasted presentation at the Sidoti Virtual Investor Conference on August 17, 2022, at 12:15 PM ET. The event will feature management discussions and 1x1 meetings with institutional investors.
Quipt focuses on providing in-home monitoring and disease management services, particularly in respiratory care. The company aims to expand its offerings to manage chronic diseases, enhancing patient care while increasing revenue per patient. The presentation will be accessible via the company’s website, with replays available post-event.